449 related articles for article (PubMed ID: 34631695)
1. Systematic Characterization of Novel Immune Gene Signatures Predicts Prognostic Factors in Hepatocellular Carcinoma.
Xu D; Wang Y; Wu J; Zhang Y; Liu Z; Chen Y; Zheng J
Front Cell Dev Biol; 2021; 9():686664. PubMed ID: 34631695
[No Abstract] [Full Text] [Related]
2. Immune landscape of hepatocellular carcinoma tumor microenvironment identifies a prognostic relevant model.
Cao H; Huang P; Qiu J; Gong X; Cao H
Heliyon; 2024 Feb; 10(3):e24861. PubMed ID: 38317886
[TBL] [Abstract][Full Text] [Related]
3. Identification and Validation of a Tumor Microenvironment-Related Gene Signature in Hepatocellular Carcinoma Prognosis.
Huang C; Zhang C; Sheng J; Wang D; Zhao Y; Qian L; Xie L; Meng Z
Front Genet; 2021; 12():717319. PubMed ID: 34899826
[No Abstract] [Full Text] [Related]
4. Identification and Analysis of Immune-Related Gene Signature in Hepatocellular Carcinoma.
Shen B; Zhang G; Liu Y; Wang J; Jiang J
Genes (Basel); 2022 Oct; 13(10):. PubMed ID: 36292719
[TBL] [Abstract][Full Text] [Related]
5. A novel natural killer-related signature to effectively predict prognosis in hepatocellular carcinoma.
Xi D; Wang J; Yang Y; Ji F; Li C; Yan X
BMC Med Genomics; 2023 Sep; 16(1):211. PubMed ID: 37674210
[TBL] [Abstract][Full Text] [Related]
6. Seven immune-related genes prognostic power and correlation with tumor-infiltrating immune cells in hepatocellular carcinoma.
Liu T; Wu H; Qi J; Qin C; Zhu Q
Cancer Med; 2020 Oct; 9(20):7440-7452. PubMed ID: 32815653
[TBL] [Abstract][Full Text] [Related]
7. Identification of a prognostic and therapeutic immune signature associated with hepatocellular carcinoma.
Peng Y; Liu C; Li M; Li W; Zhang M; Jiang X; Chang Y; Liu L; Wang F; Zhao Q
Cancer Cell Int; 2021 Feb; 21(1):98. PubMed ID: 33568167
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive Bioinformatic Analysis Reveals an Autophagy-related Gene Signature for Predicting Outcome, Immune Status, and Drug Sensitivity in Hepatocellular Carcinoma.
Liu P; Zhou Y; Zeng S; Chen X
Recent Pat Anticancer Drug Discov; 2024 Jan; ():. PubMed ID: 38204266
[TBL] [Abstract][Full Text] [Related]
9. Identification of the Tumor Immune Microenvironment and Therapeutic Biomarkers by a Novel Molecular Subtype Based on Aging-Related Genes in Hepatocellular Carcinoma.
Cai D; Zhao Z; Hu J; Dai X; Zhong G; Gong J; Qi F
Front Surg; 2022; 9():836080. PubMed ID: 35392063
[TBL] [Abstract][Full Text] [Related]
10. Identifying a Novel Endoplasmic Reticulum-Related Prognostic Model for Hepatocellular Carcinomas.
Ding F; Li J; Zhang Y; Wang C; Yu Y
Oxid Med Cell Longev; 2022; 2022():8248355. PubMed ID: 35915607
[TBL] [Abstract][Full Text] [Related]
11. Prognostic model for hepatocellular carcinoma based on anoikis-related genes: immune landscape analysis and prediction of drug sensitivity.
Zhang D; Liu S; Wu Q; Ma Y; Zhou S; Liu Z; Sun W; Lu Z
Front Med (Lausanne); 2023; 10():1232814. PubMed ID: 37502362
[TBL] [Abstract][Full Text] [Related]
12. A robust twelve-gene signature for prognosis prediction of hepatocellular carcinoma.
Ouyang G; Yi B; Pan G; Chen X
Cancer Cell Int; 2020; 20():207. PubMed ID: 32514252
[TBL] [Abstract][Full Text] [Related]
13. Development and validation of a novel immune-related prognostic model in hepatocellular carcinoma.
Wang Z; Zhu J; Liu Y; Liu C; Wang W; Chen F; Ma L
J Transl Med; 2020 Feb; 18(1):67. PubMed ID: 32046766
[TBL] [Abstract][Full Text] [Related]
14. The Landscape of the Tumor Microenvironment in Skin Cutaneous Melanoma Reveals a Prognostic and Immunotherapeutically Relevant Gene Signature.
Zhou S; Sun Y; Chen T; Wang J; He J; Lyu J; Shen Y; Chen X; Yang R
Front Cell Dev Biol; 2021; 9():739594. PubMed ID: 34660598
[TBL] [Abstract][Full Text] [Related]
15. Development of a macrophages-related 4-gene signature and nomogram for the overall survival prediction of hepatocellular carcinoma based on WGCNA and LASSO algorithm.
Yang Z; Zi Q; Xu K; Wang C; Chi Q
Int Immunopharmacol; 2021 Jan; 90():107238. PubMed ID: 33316739
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive analysis of tumour mutation burden and the immune microenvironment in hepatocellular carcinoma.
Xie F; Bai Y; Yang X; Long J; Mao J; Lin J; Wang D; Song Y; Xun Z; Huang H; Yang X; Zhang L; Mao Y; Sang X; Zhao H
Int Immunopharmacol; 2020 Dec; 89(Pt A):107135. PubMed ID: 33189609
[TBL] [Abstract][Full Text] [Related]
17. Hypoxic Characteristic in the Immunosuppressive Microenvironment of Hepatocellular Carcinoma.
Mo Z; Liu D; Rong D; Zhang S
Front Immunol; 2021; 12():611058. PubMed ID: 33679749
[No Abstract] [Full Text] [Related]
18. Construction and validation of a prognostic marker and risk model for HCC ultrasound therapy combined with WGCNA identification.
Bi Y; Jing Y; Guo L
Front Genet; 2022; 13():1017551. PubMed ID: 36263426
[No Abstract] [Full Text] [Related]
19. Identification, Verification and Pathway Enrichment Analysis of Prognosis-Related Immune Genes in Patients With Hepatocellular Carcinoma.
Zhu Z; Song M; Li W; Li M; Chen S; Chen B
Front Oncol; 2021; 11():695001. PubMed ID: 34616672
[TBL] [Abstract][Full Text] [Related]
20. Ubiquitin-proteasome system-based signature to predict the prognosis and drug sensitivity of hepatocellular carcinoma.
Zhang J; Liu L; Wang Z; Hou M; Dong Z; Yu J; Sun R; Cui G
Front Pharmacol; 2023; 14():1172908. PubMed ID: 37180696
[No Abstract] [Full Text] [Related]
[Next] [New Search]
